1Kato H,Ichinose Y,Ohta M. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung[J].New England Journal of Medicine,2004,(17):1713-1721.
2Mitsudomi T,Tada H,Ichinose Y. Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine compared with oral tegafur-uracil (UFF) in resected,stage Ⅰ B-Ⅲa non-small cell lung cancer (WJTOG 0101)[A].2011.Abstr9008.
3Olaussen KA,Dunant A,Fouret P. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J].New England Journal of Medicine,2006,(10):983-991.doi:10.1056/NEJMoa060570.
4Olaussen K A,Pierceall W E,Sprott K M. Immunohistochemical analysis of a panel of DNA repair proteins in NSCLC predict for cisplatin benefit in resected squamouscell carcinoma but not in adenocarcinoma[A].2011.Abstr9009.
5Bollineni V R,Wiegman E M,Pruim J. 18F-FDGPET 12 weeks after stereotactic body radiotherapy for stage Ⅰ non-small-cell lung cancer predicts outcome[A].2011.Abstr9010.
6Miyata1Y,Okada1 M,Okumura S. Multicenter analysis of high-resolution computed tomography and fluorodeoxyglucose-positron emission tomography/computed tomography to predict malignant grade of clinical stage Ⅰ A lung adenocarcinoma[A].2011.Abstr9011.
8Ekman1S,HarmenbergJ,Stahl.B. Phase Ⅰ doseescalation study of AXL1717:anovel targeted oral insulinlike growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung carcinoma[A].2011.Abstr9013.
9Pirker R,Pereira J R,Szczesna A. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX):an open-label randomized phased Ⅲ trial[J].The Lancet,2009,(9674):1525-1531.
10Sandler A,Gray R,PerryM C. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J].New England Journal of Medicine,2006,(24):2542-2550.doi:10.1056/NEJMoa061884.
二级参考文献14
1Yu H,Spitz MR,Mistry J,et al.Plasma levels of insulin-like growth factor-I and lung cancer risk:a case-control analysis [J].J Natl Cancer Inst,1999,91(2):151-156.
2Valentinis B,Baserga R.IGF-I receptor signalling in transformation and differentiation [J].Mol Pathol,2001,54(3):133-137.
3Pavelic J,Krizanac S,Kapitanovic S,et al.The consequences of insulin-like growth factors/receptors dysfunction in lung cancer [J].Am J Respir Cell Mol Biol,2005,32(1):65-71.
4Brognard J,Clark AS,Ni Y,et al.PKB/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation [J].Cancer Res,2001,61(4):3986-3997.
5Chun K,Kosmeder II JW,Sun S,et al.Effects of deguelin on the phosphatidylinositol 3-kinase/AKT pathway and apoptosis in premalignant human bronchial epithelial cells [J].J Natl Cancer Inst,2003,95(4):291-302.
6Balsara BR,Pei J,Mitsuuchi Y,et al.Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions [J].Carcino-genesis,2004,25(11):2053-2059.
7Quinn KA,Treston AM,Unsworth EJ,et al.Insulin-like growth factor expression in human cancer cell lines [J].J Biol Chem,1996,271(19):11477-11483.
8Furstenberger G,Senn HJ.Insulin-like growth factors and cancer [J].Lancet Oncol,2002,3(5):298-302.
9Moorehead RA,Sanchez OH,Baldwin RM,et al.Transgenic overexpression of IGF-II induces spontaneous lung tumors:a model for human lung adenocarcinoma [J].Oncogene,2003,22(6):853-857.
10Grimberg A,Cohen P.Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis [J].J Cell Physiol,2000,183(1):1-9.
